For years, scientists studying the human gut have relied on a material that most people would never expect: a jelly made from mouse tumors. Called Matrigel, it is used to grow tiny, patient‑derived versions of the intestine that help researchers understand disease, test new drugs, and explore future therapies. However, since this material comes from animal tissue, it’s unpredictable, difficult to control, and limits medical applications. 

A new study conducted by Georgia Tech researchers and partners from the Children’s Hospital of Philadelphia and University of Pennsylvania offers a promising alternative. 

The work includes contributions from Andrés García, Regents’ Professor in the George W. Woodruff School of Mechanical Engineering and Executive Director of the Parker H. Petit Institute for Bioengineering and Bioscience, whose research focuses on how engineered materials can guide cell behavior. Instead of relying on a biological mixture with hundreds of variable components, the team created a fully synthetic gel designed to give intestinal stem cells exactly what they need to grow and organize into healthy tissue. 

To build it, the researchers analyzed the genetic signals of human intestinal cells to understand what kind of environment they naturally prefer. They found that these cells latch onto collagen‑like structures and reshape their surroundings as they expand. Using that information, the team engineered a customizable gel that mimics those cues, without using any animal‑derived ingredients. 

The results were striking. Human intestinal cells grown in the synthetic gel formed realistic, well‑organized small-scale digestive tract models that closely match those grown in the traditional animal‑derived material. They maintained the same cell types, developed the same structures, and preserved patient‑specific features. 

The implications reach far beyond the lab bench. 

A fully synthetic, precisely defined gel means researchers can grow small-scale organs more consistently and ethically, reducing reliance on animal tissue and improving reproducibility. It also opens the door to future medical applications, from personalized drug testing to regenerative therapies, where animal‑based materials simply can’t be used. 

"Reproducible, well-defined culture conditions are essential to generating reliable data from patient-derived organoids in human disease research, and we were glad to contribute to work that brings the field a real synthetic alternative to Matrigel,” said Kathryn Hamilton, a co-author of the study. Hamilton is an associate professor at the University of Pennsylvania and a primary investigator at Children’s Hospital of Philadelphia.  

By replacing one of the biggest barriers in organoid science, this work moves the field closer to a future where patient‑specific tissues can be grown safely, reliably, and at scale. 

“We are excited about engineering this synthetic matrix as an alternative to natural materials and expect that it will accelerate human organoid research and clinical applications,” García said.